Large prospective study of ramipril in patients with hypertension

Norman M Kaplan, L. E. Sproul, W. S. Mulcahy

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

The results of controlled trials demonstrate that ramipril lowers blood pressure in hypertensive patients, has a long duration of action suitable for once-daily administration in most patients, and is well tolerated. To assess the efficacy and safety of ramipril in a large cross-section of patients, we conducted a multicenter, open-label, prospective study, in which 591 men or women with essential hypertension (diastolic blood pressure ≥ 95 and ≤ 114 mmHg) received ramipril on a regimen of 1.25 to 10 mg once daily for 8 weeks. Forty-one percent of the patients required 2.5 mg and 81% required ≤ 5 mg once daily at study completion. Compared with baseline, ramipril reduced mean systolic/diastolic blood pressure by 19.9/14.7 mmHg (P < 0.001/P < 0.001). Ramipril reduced diastolic blood pressure to ≤ 90 mmHg or by at least 10 mmHg in 84.1% of the patients. Response rates were similar regardless of age, gender, and race. No patient stopped ramipril because of an adverse event or experienced an unexpected adverse event. In our real-world study, low-dose ramipril given once daily controlled blood pressure in most patients and was well tolerated.

Original languageEnglish (US)
Pages (from-to)810-818
Number of pages9
JournalClinical Therapeutics
Volume15
Issue number5
StatePublished - 1993

Fingerprint

Ramipril
Prospective Studies
Blood Pressure
Hypertension
Safety

ASJC Scopus subject areas

  • Pharmacology

Cite this

Large prospective study of ramipril in patients with hypertension. / Kaplan, Norman M; Sproul, L. E.; Mulcahy, W. S.

In: Clinical Therapeutics, Vol. 15, No. 5, 1993, p. 810-818.

Research output: Contribution to journalArticle

Kaplan, NM, Sproul, LE & Mulcahy, WS 1993, 'Large prospective study of ramipril in patients with hypertension', Clinical Therapeutics, vol. 15, no. 5, pp. 810-818.
Kaplan, Norman M ; Sproul, L. E. ; Mulcahy, W. S. / Large prospective study of ramipril in patients with hypertension. In: Clinical Therapeutics. 1993 ; Vol. 15, No. 5. pp. 810-818.
@article{edc2c2e76d784100b6401ccc7deeca4a,
title = "Large prospective study of ramipril in patients with hypertension",
abstract = "The results of controlled trials demonstrate that ramipril lowers blood pressure in hypertensive patients, has a long duration of action suitable for once-daily administration in most patients, and is well tolerated. To assess the efficacy and safety of ramipril in a large cross-section of patients, we conducted a multicenter, open-label, prospective study, in which 591 men or women with essential hypertension (diastolic blood pressure ≥ 95 and ≤ 114 mmHg) received ramipril on a regimen of 1.25 to 10 mg once daily for 8 weeks. Forty-one percent of the patients required 2.5 mg and 81{\%} required ≤ 5 mg once daily at study completion. Compared with baseline, ramipril reduced mean systolic/diastolic blood pressure by 19.9/14.7 mmHg (P < 0.001/P < 0.001). Ramipril reduced diastolic blood pressure to ≤ 90 mmHg or by at least 10 mmHg in 84.1{\%} of the patients. Response rates were similar regardless of age, gender, and race. No patient stopped ramipril because of an adverse event or experienced an unexpected adverse event. In our real-world study, low-dose ramipril given once daily controlled blood pressure in most patients and was well tolerated.",
author = "Kaplan, {Norman M} and Sproul, {L. E.} and Mulcahy, {W. S.}",
year = "1993",
language = "English (US)",
volume = "15",
pages = "810--818",
journal = "Clinical Therapeutics",
issn = "0149-2918",
publisher = "Excerpta Medica",
number = "5",

}

TY - JOUR

T1 - Large prospective study of ramipril in patients with hypertension

AU - Kaplan, Norman M

AU - Sproul, L. E.

AU - Mulcahy, W. S.

PY - 1993

Y1 - 1993

N2 - The results of controlled trials demonstrate that ramipril lowers blood pressure in hypertensive patients, has a long duration of action suitable for once-daily administration in most patients, and is well tolerated. To assess the efficacy and safety of ramipril in a large cross-section of patients, we conducted a multicenter, open-label, prospective study, in which 591 men or women with essential hypertension (diastolic blood pressure ≥ 95 and ≤ 114 mmHg) received ramipril on a regimen of 1.25 to 10 mg once daily for 8 weeks. Forty-one percent of the patients required 2.5 mg and 81% required ≤ 5 mg once daily at study completion. Compared with baseline, ramipril reduced mean systolic/diastolic blood pressure by 19.9/14.7 mmHg (P < 0.001/P < 0.001). Ramipril reduced diastolic blood pressure to ≤ 90 mmHg or by at least 10 mmHg in 84.1% of the patients. Response rates were similar regardless of age, gender, and race. No patient stopped ramipril because of an adverse event or experienced an unexpected adverse event. In our real-world study, low-dose ramipril given once daily controlled blood pressure in most patients and was well tolerated.

AB - The results of controlled trials demonstrate that ramipril lowers blood pressure in hypertensive patients, has a long duration of action suitable for once-daily administration in most patients, and is well tolerated. To assess the efficacy and safety of ramipril in a large cross-section of patients, we conducted a multicenter, open-label, prospective study, in which 591 men or women with essential hypertension (diastolic blood pressure ≥ 95 and ≤ 114 mmHg) received ramipril on a regimen of 1.25 to 10 mg once daily for 8 weeks. Forty-one percent of the patients required 2.5 mg and 81% required ≤ 5 mg once daily at study completion. Compared with baseline, ramipril reduced mean systolic/diastolic blood pressure by 19.9/14.7 mmHg (P < 0.001/P < 0.001). Ramipril reduced diastolic blood pressure to ≤ 90 mmHg or by at least 10 mmHg in 84.1% of the patients. Response rates were similar regardless of age, gender, and race. No patient stopped ramipril because of an adverse event or experienced an unexpected adverse event. In our real-world study, low-dose ramipril given once daily controlled blood pressure in most patients and was well tolerated.

UR - http://www.scopus.com/inward/record.url?scp=0027421914&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027421914&partnerID=8YFLogxK

M3 - Article

VL - 15

SP - 810

EP - 818

JO - Clinical Therapeutics

JF - Clinical Therapeutics

SN - 0149-2918

IS - 5

ER -